Pipeline

  • AVT02

    Biosimilar candidate
    High-concentration adalimumab
    Reference biologic
    HUMIRA®
    Therapeutic area
    Immunology

    Approved by

    • CHMP
    • Health Canada
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT04

    Biosimilar candidate
    ustekinumab
    Reference biologic
    STELARA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT23*

    Biosimilar candidate
    omalizumab
    Reference biologic
    XOLAIR®
    Therapeutic area
    Respiratory
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT03

    Biosimilar candidate
    densosumab
    Reference biologic
    PROLIA/XGEVA®
    Therapeutic area
    Immunilogy/Oncology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch